Skip to main content
Clinical Trials/JPRN-UMIN000002214
JPRN-UMIN000002214
Completed
Phase 2

Safety and efficacy of cord blood transplantation for hematologic malignancies (OCU 9-2) - Safety and efficacy of cord blood transplantation for hematologic malignancies (OCU 9-2)

Hematology, Osaka City University, Graduate School of Medicine0 sites20 target enrollmentJuly 17, 2009

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Acute myeloid leukemia AML with multilineage dysplasia Myelodysplastic syndrome Acute lymphoblastic leukemia Chronic myeloid leukemia Adult T cell leukemia/lymphoma Malignant lymphoma
Sponsor
Hematology, Osaka City University, Graduate School of Medicine
Enrollment
20
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 17, 2009
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Hematology, Osaka City University, Graduate School of Medicine

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. Dysfunction of major organ which meets any of the following criteria. a. T\-Bil \> 2\.0mg/dl b. Cre \> 2\.0mg/dl c. EF \>30% d. %VC \<30%, FEV1\.0% \<40% or SaO2 \< 50mmHg on room air (SpO2 \<90%) e. AST: beyond 3 times of UNL 2\. Active infection 3\. Poorly controlled diabetes mellitus despite the use of insulin 4\. Poorly controlled hypertention 5\. Severe complications including heart failure, coronary failure, myocardial infarction within the last 3 months, liver cirrhosis and interstitial pneumonia 6\. Pregnant, nursing of possible fertile woman 7\. Severe mental disorder who is unlikely to be able to participate in the study 8\. A history of hypersensitivity or allergy to any drugs in conditioning regimen of this transplantation 9\. HIV antibody positivity 10\. No indication for this study judged by physician in charge

Outcomes

Primary Outcomes

Not specified

Similar Trials